Literature DB >> 21422414

Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.

Hagop Kantarjian1, Jorge Cortes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21422414      PMCID： PMC4979098          DOI： 10.1200/JCO.2010.33.9176

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

Review 1.  Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.

Authors:  Hagop Kantarjian; Charles Schiffer; Dan Jones; Jorge Cortes
Journal:  Blood       Date:  2007-11-30       Impact factor: 22.113

2.  Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.

Authors:  Francisco Cervantes; Pilar López-Garrido; María-Isabel Montero; Fermín Jonte; Jesús Martínez; Juan-Carlos Hernández-Boluda; María Calbacho; Anna Sureda; Gloria Pérez-Rus; José B Nieto; Cristina Pérez-López; José Román-Gómez; Marcos González; Arturo Pereira; Dolors Colomer
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

3.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.

Authors:  Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Daniel Jones; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

4.  Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.

Authors:  Hagop M Kantarjian; Jianqin Shan; Daniel Jones; Susan O'Brien; Mary Beth Rios; Elias Jabbour; Jorge Cortes
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

5.  BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

Authors:  Richard D Press; Zac Love; Ashlie A Tronnes; Rui Yang; Thuan Tran; Solange Mongoue-Tchokote; Motomi Mori; Michael J Mauro; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2006-02-07       Impact factor: 22.113

6.  Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.

Authors:  Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis J Giles; Mary Beth Rios; Stefan H Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

7.  Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

Authors:  Elias Jabbour; Hagop M Kantarjian; Lynne V Abruzzo; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Journal:  Blood       Date:  2007-07-11       Impact factor: 22.113

Review 8.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

9.  Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors:  Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

10.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245
View more
  9 in total

1.  Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.

Authors:  Tariq I Mughal; Jerald P Radich; Richard A Van Etten; Alfonso Quintás-Cardama; Tomasz Skorski; Farhad Ravandi; Daniel J DeAngelo; Carlo Gambacorti-Passerini; Giovanni Martinelli; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

2.  Selective surface marker and miRNA profiles of CD34+ blast-derived microvesicles in chronic myelogenous leukemia.

Authors:  Junli Zhang; Aiqi Zhao; Li Sun; Weiqun Chen; Haiming Zhang; Zhichao Chen; Fang Liu
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

3.  Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.

Authors:  Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Elias Jabbour; Jianqin Shan; Jorge Cortes
Journal:  Cancer       Date:  2012-02-27       Impact factor: 6.860

Review 4.  Selecting the best frontline treatment in chronic myeloid leukemia.

Authors:  Musa Yilmaz; Yasmin Abaza; Elias Jabbour
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 5.  Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.

Authors:  Zehra Narlı Özdemir; Necati Alp Kılıçaslan; Musa Yılmaz; Ahmet Emre Eşkazan
Journal:  Int J Hematol       Date:  2022-09-05       Impact factor: 2.319

Review 6.  Clinical trials in chronic myeloid leukemia.

Authors:  Susanne Saussele; Markus Pfirrmann
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

7.  Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.

Authors:  B Uz; O Bektas; E Eliacık; H Goker; Y Erbilgin; M Sayitoglu; N Sayinalp; S Aksu; Y Buyukasik; O Ozcebe; I C Haznedaroglu
Journal:  Case Rep Hematol       Date:  2011-11-03

8.  A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.

Authors:  T L Holyoake; M Copland; G A Horne; J Stobo; C Kelly; A Mukhopadhyay; A L Latif; J Dixon-Hughes; L McMahon; P Cony-Makhoul; J Byrne; G Smith; S Koschmieder; T H BrÜmmendorf; P Schafhausen; P Gallipoli; F Thomson; W Cong; R E Clark; D Milojkovic; G V Helgason; L Foroni; F E Nicolini
Journal:  Leukemia       Date:  2020-01-10       Impact factor: 11.528

Review 9.  Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.

Authors:  Sandra E Kurtin; Lisa Matta
Journal:  J Adv Pract Oncol       Date:  2013-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.